Insider Buying: OPKO Health, Inc. (NASDAQ:OPK) CEO Acquires $98,500.00 in Stock

OPKO Health, Inc. (NASDAQ:OPKGet Rating) CEO Phillip Md Et Al Frost bought 50,000 shares of OPKO Health stock in a transaction on Monday, September 19th. The stock was purchased at an average price of $1.97 per share, with a total value of $98,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 197,506,694 shares of the company’s stock, valued at approximately $389,088,187.18. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Wednesday, September 21st, Phillip Md Et Al Frost bought 50,000 shares of OPKO Health stock. The stock was purchased at an average price of $1.91 per share, with a total value of $95,500.00.
  • On Thursday, September 15th, Phillip Md Et Al Frost bought 200,000 shares of OPKO Health stock. The stock was purchased at an average price of $2.06 per share, with a total value of $412,000.00.
  • On Wednesday, August 17th, Phillip Md Et Al Frost acquired 200,000 shares of OPKO Health stock. The shares were bought at an average price of $2.54 per share, for a total transaction of $508,000.00.
  • On Friday, August 5th, Phillip Md Et Al Frost acquired 350,000 shares of OPKO Health stock. The shares were bought at an average price of $2.29 per share, for a total transaction of $801,500.00.

OPKO Health Stock Performance

OPK opened at $1.89 on Friday. The firm’s 50-day moving average price is $2.35 and its 200-day moving average price is $2.78. The company has a market cap of $1.46 billion, a P/E ratio of -6.52 and a beta of 1.75. OPKO Health, Inc. has a 52-week low of $1.85 and a 52-week high of $5.25. The company has a quick ratio of 1.91, a current ratio of 2.30 and a debt-to-equity ratio of 0.12.

OPKO Health (NASDAQ:OPKGet Rating) last issued its earnings results on Thursday, August 4th. The biotechnology company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). The firm had revenue of $309.90 million during the quarter, compared to analysts’ expectations of $326.87 million. OPKO Health had a negative net margin of 14.18% and a negative return on equity of 7.72%. OPKO Health’s quarterly revenue was down 30.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.03) EPS. As a group, equities analysts anticipate that OPKO Health, Inc. will post -0.38 EPS for the current fiscal year.

Institutional Investors Weigh In On OPKO Health

Large investors have recently bought and sold shares of the company. Swiss National Bank boosted its position in OPKO Health by 7.5% in the 1st quarter. Swiss National Bank now owns 1,047,200 shares of the biotechnology company’s stock worth $3,602,000 after purchasing an additional 72,900 shares in the last quarter. BNP Paribas Arbitrage SA raised its stake in OPKO Health by 19.2% in the 4th quarter. BNP Paribas Arbitrage SA now owns 165,928 shares of the biotechnology company’s stock valued at $798,000 after purchasing an additional 26,707 shares during the last quarter. Columbia Asset Management acquired a new position in OPKO Health in the 4th quarter valued at $67,000. E Fund Management Co. Ltd. raised its stake in OPKO Health by 190.1% in the 1st quarter. E Fund Management Co. Ltd. now owns 81,338 shares of the biotechnology company’s stock valued at $280,000 after purchasing an additional 53,299 shares during the last quarter. Finally, Levin Capital Strategies L.P. acquired a new position in OPKO Health in the 1st quarter valued at $52,000. Hedge funds and other institutional investors own 27.83% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Piper Sandler cut their price objective on shares of OPKO Health from $5.00 to $4.00 and set an “overweight” rating on the stock in a report on Friday, August 5th.

OPKO Health Company Profile

(Get Rating)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.

Featured Articles

Insider Buying and Selling by Quarter for OPKO Health (NASDAQ:OPK)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.